With its predominant expression in hematopoietic cell linages and its multilateral impact on key immune cell types involved in anti-tumor action, pharmacological blockade of HPK1 may provide superior anti-tumor potential [7]. The gene discussed is MAP4K1; the disease is neoplasm.